RAPT Therapeutics (RAPT) Liabilities and Shareholders Equity (2020 - 2024)
Historic Liabilities and Shareholders Equity for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $108.5 million.
- Therapeutics' Liabilities and Shareholders Equity fell 4569.17% to $108.5 million in Q3 2024 from the same period last year, while for Dec 2024 it was $391.5 million, marking a year-over-year decrease of 5351.52%. This contributed to the annual value of $173.3 million for FY2023, which is 3488.99% down from last year.
- According to the latest figures from Q3 2024, Therapeutics' Liabilities and Shareholders Equity is $108.5 million, which was down 4569.17% from $127.2 million recorded in Q2 2024.
- Over the past 5 years, Therapeutics' Liabilities and Shareholders Equity peaked at $266.2 million during Q4 2022, and registered a low of $105.9 million during Q1 2021.
- Over the past 5 years, Therapeutics' median Liabilities and Shareholders Equity value was $187.5 million (recorded in 2022), while the average stood at $179.5 million.
- As far as peak fluctuations go, Therapeutics' Liabilities and Shareholders Equity soared by 7705.9% in 2022, and later tumbled by 4569.17% in 2024.
- Quarter analysis of 5 years shows Therapeutics' Liabilities and Shareholders Equity stood at $119.0 million in 2020, then skyrocketed by 66.96% to $198.6 million in 2021, then surged by 34.02% to $266.2 million in 2022, then tumbled by 34.89% to $173.3 million in 2023, then plummeted by 37.42% to $108.5 million in 2024.
- Its Liabilities and Shareholders Equity stands at $108.5 million for Q3 2024, versus $127.2 million for Q2 2024 and $155.8 million for Q1 2024.